OMERS ADMINISTRATION Corp Has $15.96 Million Holdings in AbbVie Inc. $ABBV

OMERS ADMINISTRATION Corp decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 17.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,982 shares of the company’s stock after selling 17,900 shares during the period. OMERS ADMINISTRATION Corp’s holdings in AbbVie were worth $15,960,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie in the 2nd quarter valued at about $25,000. TD Capital Management LLC grew its holdings in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares in the last quarter. Spurstone Advisory Services LLC acquired a new stake in AbbVie in the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie in the 2nd quarter valued at approximately $36,000. Finally, Bear Mountain Capital Inc. raised its position in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after buying an additional 173 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

Shares of ABBV stock opened at $226.72 on Monday. The stock has a market cap of $400.69 billion, a P/E ratio of 107.96, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The company has a fifty day moving average price of $227.71 and a two-hundred day moving average price of $207.01. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is currently 524.24%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $170.00 to $270.00 in a research report on Wednesday, September 17th. Daiwa America raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. Raymond James Financial set a $256.00 target price on shares of AbbVie in a research report on Monday, November 3rd. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, HSBC set a $225.00 price objective on shares of AbbVie in a research note on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $241.85.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.